Program News
News and stories about the UNC Lineberger Pancreatic Cancer Center of Excellence
-
NIH Director’s blog features pancreatic cancer research led by Der and Cox
NIH Director Monica Bertagnolli, MD, wrote about research led by UNC Lineberger’s Channing Der, PhD, and Adrienne Cox, PhD, that provided the most comprehensive molecular portrait of the workings of KRAS.
-
Scientific symposium highlights latest developments in pancreatic cancer research
UNC Lineberger’s 47th annual scientific symposium featured 17 presentations from faculty at UNC Lineberger and institutions across the United States.
-
Molecular pathway that impacts pancreatic cancer progression and response to treatment detailed
UNC Lineberger researchers have established the most comprehensive molecular portrait of the workings of KRAS, a key cancer-causing gene, and how its activities impact pancreatic cancer outcomes.
-
Yeh, Johnson awarded five-year, $3.2 million research grant from NCI
The grant will support the first metastatic pancreatic cancer trial in the country to evaluate whether selecting treatment by tumor subtype will help patients match to more effective first-line therapies.
-
PROCLAIM Study open to accrual
The PROmoting CLinicAl TrIal EngageMent for Pancreatic Cancer App Study (PROCLAIM Study), which is focused on breaking down barriers to diverse clinical trial population recruitment, is enrolling patients.
-
Two pancreatic cancer clinical trials now recruiting at UNC Lineberger
We have recently been added as a study location for two phase I clinical trials currently recruiting patients with pancreatic ductal adenocarcinoma (PDAC).
-
Inspired research: A conversation with Kirsten Bryant, PhD
Kirsten Bryant, PhD, shares what motivates her in the lab, how mentorship and advocacy have fueled her passion for pancreatic cancer research, and why she’s encouraged by progress made in the past decade.
-
Pancreatic Cancer Action Network names Yeh to scientific and medical advisory board
Jen Yeh, MD, has been appointed to the Pancreatic Cancer Action Network’s scientific and medical advisory board, which is comprised of leading scientists, clinicians and healthcare professionals across the United States.